Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152254 · ClinicalTrials.gov registry record · Phase 2
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
A Phase 2 study of Metastatic Malignant Neoplasm and Recurrent Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 1,362
- Enrollment target
- 1
- Study location
NCT02152254: Active Phase 2 study of Metastatic Malignant Neoplasm and Recurrent Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.
NCT02152254 is a Phase 2 study of Metastatic Malignant Neoplasm and Recurrent Malignant Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,362 participants, above the 248-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (449% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02152254, a Phase 2 study of Metastatic Malignant Neoplasm and Recurrent Malignant Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,362 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized clinical trial studies how molecular profiling and targeted therapy work in treating patients with cancer that has spread to other places in the body compared to standard treatment. Information about genetic differences in a patient's tumor can be used to choose treatment that may target the tumor. It is not yet validated whether selecting treatment after studying the genetic changes that are associated with cancer in a patient's tumor is a better way to treat patients with metastatic cancer compared to therapy not based on studying the genetic changes that are associated with cancer.
Primary Outcome
Progression-free survival (PFS) of patients treated with a targeted therapy selected on the basis of mutational analysis of the tumor compared with PFS of those whose treatment is not selected based on alteration analysis.
Conditions Studied
Interventions
- DRUG Targeted Therapy Based on Molecular Profiling
- DRUG Standard-of-Care Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,362 participants |
| Start Date | 2014-05-13 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
What the registry record for NCT02152254 still lists
NCT02152254 is an interventional study that assigns participants to a tested intervention. Its 1,362 participants enrollment target places it among the larger protocols in the corpus, above the 248-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (449% higher).
The record links to 2 conditions, with Metastatic Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Targeted Therapy Based on Molecular Profiling is the first listed.
NCT02152254 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02152254 about?
NCT02152254 is a clinical study titled "Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)". This randomized clinical trial studies how molecular profiling and targeted therapy work in treating patients with cancer that has spread to other places in the body compared to standard treatment. Information about genetic differences in a patient's tumor can be used to choose treatment that may ta...
What is the current status of trial NCT02152254?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,362 participants. The study started on 2014-05-13. Estimated completion is 2030-12-31.
What conditions does trial NCT02152254 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm.
What interventions are being tested in trial NCT02152254?
The interventions under investigation include: Targeted Therapy Based on Molecular Profiling (DRUG), Standard-of-Care Therapy (DRUG).
Who is sponsoring clinical trial NCT02152254?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152254 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02152254's enrollment target sits among peer trials
1,362 2nd of 15 the highest of 15 other Metastatic Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI